2025
Changes in glucose level during chemotherapy treatment in patients with stage I–IV breast cancer
Schnell P, Kassem M, Miah A, Ramaswamy B, Williams N, Cherian M, Stover D, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, Sudheendra P, Ormiston K, Mezzanotte J, Orchard T, Lustberg M. Changes in glucose level during chemotherapy treatment in patients with stage I–IV breast cancer. Clinical Breast Cancer 2025 PMID: 40541466, DOI: 10.1016/j.clbc.2025.05.021.Peer-Reviewed Original ResearchStage I-IV breast cancerBreast cancerGlucose dysregulationGlucose levelsBlood glucoseChemotherapy treatment of patientsChemotherapy treatmentNCI-designated Comprehensive Cancer CenterTreatment of patientsComprehensive cancer centerBaseline glucose levelsRandom blood glucoseRandom glucose levelsChemotherapy regimenBlood glucose levelsChemotherapyStatistically significant changesHistopathological dataDiabetes mellitusWorsening morbidityCancer CenterBaseline variablesPatientsStudy populationAppropriate management
2024
Prenatal and infant exposure to antibiotics and subsequent risk of neuropsychiatric disorders in children: A nationwide birth cohort study in South Korea
Oh J, Woo H, Kim H, Park J, Lee M, Rahmati M, Rhee S, Min C, Koyanagi A, Smith L, Fond G, Boyer L, Kim M, Shin J, Lee S, Yon D. Prenatal and infant exposure to antibiotics and subsequent risk of neuropsychiatric disorders in children: A nationwide birth cohort study in South Korea. Psychiatry Research 2024, 340: 116117. PMID: 39128166, DOI: 10.1016/j.psychres.2024.116117.Peer-Reviewed Original ResearchConceptsRisk of neuropsychiatric disordersNeuropsychiatric disordersAntibiotic exposureHazard ratioNationwide birth cohort studyHealth Screening CohortPostnatal lifeConfidence intervalsBirth cohort studyFollow-up durationDuration of prescriptionExposure to antibioticsEstimates of hazard ratiosLong-term riskScreening cohortChildhood neuropsychiatric disordersMaternal obesityPropensity score matchingAntibiotic prescriptionsPotential long-term risksCohort studyExposure statusIncreased riskBaseline variablesFamily factorsAssociation of neighborhood socioeconomic status with echocardiographic parameters and re-admission following transcatheter aortic valve replacement.
Hameed I, Todice M, Ahmed A, Higaki A, Mubasher A, Agarwal R, Williams M. Association of neighborhood socioeconomic status with echocardiographic parameters and re-admission following transcatheter aortic valve replacement. Minerva Cardioangiologica 2024, 72: 640-648. PMID: 38842244, DOI: 10.23736/s2724-5683.24.06541-4.Peer-Reviewed Original ResearchNeighborhood socioeconomic statusSocioeconomic statusAssociation of neighborhood socioeconomic statusSocioeconomic groupsHigher neighborhood socioeconomic statusPatients of low socioeconomic statusTranscatheter aortic valve replacementSociety of Thoracic SurgeonsIncreasing social deprivationElectronic health recordsLow socioeconomic statusRisk factor adjustmentTranscatheter aortic valve replacement procedureAortic valve gradientBaseline variablesAortic valve replacementRisk of mortalityHealth recordsHealth systemAssociated with shorter durationSocial deprivationValve gradientRisk scoreValve replacementVariables associated with numberAssociations between fasting glucose rate-of-change and the missense variant, rs373863828, in an adult Samoan cohort
Rivara A, Russell E, Carlson J, Pomer A, Naseri T, Reupena M, Manna S, Viali S, Minster R, Weeks D, DeLany J, Kershaw E, McGarvey S, Hawley N. Associations between fasting glucose rate-of-change and the missense variant, rs373863828, in an adult Samoan cohort. PLOS ONE 2024, 19: e0302643. PMID: 38829901, PMCID: PMC11146712, DOI: 10.1371/journal.pone.0302643.Peer-Reviewed Original ResearchConceptsType 2 diabetesAllele of rs373863828Body mass indexFasting GlucoseAdult SamoansDevelopment of type 2 diabetesOdds of type 2 diabetesReduction of modifiable risk factorsRs373863828 genotypeAssociated with higher body mass indexType 2 diabetes developmentGlucose rate of changeMass indexHousehold asset scoreUrbanization of residenceHigher Body Mass IndexRisk factorsModifiable risk factorsRate of changeBaseline variablesMultivariate linear regressionPhysical activityDiabetes preventionType 2 diabetes mellitusSmoking status
2023
Mechanical thrombectomy for the treatment of primary and secondary anterior cerebral artery occlusions: insights from STAR
Dabhi N, Kumar J, Ironside N, Kellogg R, Sowlat M, Uchida K, Maier I, Al Kasab S, Jabbour P, Kim J, Wolfe S, Rai A, Starke R, Psychogios M, Samaniego E, Arthur A, Yoshimura S, Cuellar H, Howard B, Alawieh A, Romano D, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Levitt M, Brinjikji W, Moss M, Dumont T, Williamson R, Navia P, Kan P, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta A, Park M. Mechanical thrombectomy for the treatment of primary and secondary anterior cerebral artery occlusions: insights from STAR. Journal Of NeuroInterventional Surgery 2023, 16: 1282-1287. PMID: 37968114, DOI: 10.1136/jnis-2023-020997.Peer-Reviewed Original ResearchConceptsMechanical thrombectomyProcedural outcomesCerebral arteryAnterior cerebral artery occlusionEfficacy of mechanical thrombectomyAnterior cerebral arteryMann-Whitney U testMT-treatedCerebral artery occlusionRetrospective reviewBaseline characteristicsClinical outcomesOcclusion groupStudy cohortArtery occlusionFunctional outcomesBaseline variablesIdeal patientStroke thrombectomyMann-WhitneyPatientsU testCategorical variablesThrombectomyOcclusionDose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysisSex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interactionPersonalized symptom clusters that predict depression treatment outcomes: A replication of machine learning methods
Chen Y, Stewart J, Ge J, Cheng B, Chekroud A, Hellerstein D. Personalized symptom clusters that predict depression treatment outcomes: A replication of machine learning methods. Journal Of Affective Disorders Reports 2023, 11: 100470. DOI: 10.1016/j.jadr.2023.100470.Peer-Reviewed Original ResearchHamilton Rating ScaleSymptom clustersTreatment trajectoriesQuick InventoryTreatment outcomesDouble-blind clinical trialDepressive Symptomatology-Self ReportRating ScaleBest baseline predictorsHAM-D scoresDepression treatment outcomesAnxiety disorder diagnosisQIDS-SR16Depressive illnessEscitalopram monotherapyBaseline variablesClinical trialsBaseline predictorsTreatment efficacyUnipolar depressionDifferent treatment trajectoriesTreatment planLogistic regressionDisorder diagnosisDual treatment
2022
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patientsReal‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease
Nagpal S, Scierka LE, Castro‐Dominguez Y, Kansal D, Kunnirickal S, Hussain Y, Love K, Aboian E, Smolderen KG, Mena‐Hurtado C. Real‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease. Catheterization And Cardiovascular Interventions 2022, 100: 776-784. PMID: 36129818, DOI: 10.1002/ccd.30405.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsManual compressionClosure deviceCommon femoral artery diseaseVascular Quality Initiative databaseFemoral artery diseasePropensity-matched cohortPseudoaneurysm rateRetroperitoneal bleedingArtery diseaseRetrospective reviewMean ageBaseline variablesInstitutional databaseNonsignificant reductionNonsignificant decreaseVascular interventionsMortality ratePatientsCompression useCollagen plugDiseaseInitiative databaseProcedural metricsDevice usePredictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study
Wallach JD, Gueorguieva R, Phan H, Witkiewitz K, Wu R, O'Malley SS. Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcohol Clinical And Experimental Research 2022, 46: 1331-1339. PMID: 35616436, PMCID: PMC9887652, DOI: 10.1111/acer.14877.Peer-Reviewed Original ResearchConceptsHeavy drinking daysWeeks of treatmentAlcohol use disorderDependence Scale scoresDrinking daysScale scoreDays abstinentPredictors of abstinenceConsecutive weeksUse disordersDrinking levelsCOMBINE StudyOlder subjectsRandomized placebo-controlled trialPlacebo-controlled trialEfficacy of naltrexoneMultiple patient characteristicsTrials of medicationsBehavioral intervention studyPatient characteristicsFuture trialsBaseline variablesCombined PharmacotherapiesYoung subjectsComplete abstinencePhenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2021
Increased mortality with resuscitative endovascular balloon occlusion of the aorta only mitigated by strong unmeasured confounding: An expanded analysis using the National Trauma Data Bank
Linderman GC, Lin W, Becher RD, Maung AA, Bhattacharya B, Davis KA, Schuster KM. Increased mortality with resuscitative endovascular balloon occlusion of the aorta only mitigated by strong unmeasured confounding: An expanded analysis using the National Trauma Data Bank. Journal Of Trauma And Acute Care Surgery 2021, 91: 790-797. PMID: 33951027, PMCID: PMC8547242, DOI: 10.1097/ta.0000000000003265.Peer-Reviewed Original ResearchConceptsAcute kidney injuryResuscitative endovascular balloon occlusionLower extremity amputationEndovascular balloon occlusionBalloon occlusionExtremity amputationTraumatic injuryTreatment weightingREBOA placementNational Trauma Data BankInverse probabilityPlacement of REBOATrauma Data BankSevere traumatic injuryMortality effectsUnmeasured confoundersNoncompressible torso hemorrhagePotent confounderTQIP dataTQIP databaseAortic injuryKidney injuryRetrospective studyInjury patternsBaseline variablesImproved outcomes using laparoscopy for emergency colectomy after mitigating bias by negative control exposure analysis
Linderman GC, Lin W, Sanghvi MR, Becher RD, Maung AA, Bhattacharya B, Davis KA, Schuster KM. Improved outcomes using laparoscopy for emergency colectomy after mitigating bias by negative control exposure analysis. Surgery 2021, 171: 305-311. PMID: 34332782, DOI: 10.1016/j.surg.2021.06.048.Peer-Reviewed Original ResearchConceptsOpen surgeryEmergency colectomyNational Surgical Quality Improvement Program dataQuality Improvement Program dataPostoperative septic shockLow-risk patientsSurgical site infectionPatients meeting criteriaColorectal emergenciesElective colectomyUnderwent laparoscopyHospital stayOverall morbidityNationwide registryAnastomotic leakColectomy casesConverted groupSeptic shockSite infectionPatient selectionBaseline variablesImproved outcomesLaparoscopic surgeryTreatment weightingColectomyClinical and vital sign changes associated with late-onset sepsis in very low birth weight infants at 3 NICUs
Sullivan BA, Nagraj VP, Berry KL, Fleiss N, Rambhia A, Kumar R, Wallman-Stokes A, Vesoulis ZA, Sahni R, Ratcliffe S, Lake DE, Moorman JR, Fairchild KD. Clinical and vital sign changes associated with late-onset sepsis in very low birth weight infants at 3 NICUs. Journal Of Neonatal-Perinatal Medicine 2021, 14: 553-561. PMID: 33523025, PMCID: PMC8316489, DOI: 10.3233/npm-200578.Peer-Reviewed Original ResearchConceptsLate-onset sepsisLow birth weight infantsBirth weight infantsClinical signsWeight infantsHeart rateBaseline risk factorsVital sign changesNon-infectious conditionsAbnormal CBCFirst sepsisAbdominal distensionVLBW infantsCentral cathetersMechanical ventilationPremature infantsPostnatal ageBaseline variablesClinician documentationRisk factorsClinical changesSepsisInfantsVital signsLogistic regression
2020
Outpatient Cost-effectiveness Study of Hyperkalemia Management
Desai N, Rowan C, Alvarez P, Fogli J, Coca S. Outpatient Cost-effectiveness Study of Hyperkalemia Management. Journal Of Cardiac Failure 2020, 26: s115. DOI: 10.1016/j.cardfail.2020.09.332.Peer-Reviewed Original ResearchOutpatient costsOptum's de-identified ClinformaticsEnd-stage renal diseaseMatched-cohort designData Mart DatabaseTreatment of hyperkalemiaMedicare Advantage populationCost-effectiveness studiesReal-world evidenceMEq/LCongestive HFHK cohortHyperkalemia managementPotassium bindersIndex dateCohort studyRenal diseaseOutpatient outcomesMean ageBaseline variablesInclusion criteriaPatiromerLarge cohortStudy populationCensoring event
2019
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
Gupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 254. PMID: 31533832, PMCID: PMC6751819, DOI: 10.1186/s40425-019-0731-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD8 AntigensFemaleFollow-Up StudiesGene Expression ProfilingHumansInterferon Regulatory Factor-1MaleMelanomaMiddle AgedMonitoring, ImmunologicPrognosisProgrammed Cell Death 1 Ligand 2 ProteinProgression-Free SurvivalReal-Time Polymerase Chain ReactionRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSkin NeoplasmsConceptsCompanion diagnostic testsImmunotherapy outcomesMelanoma patientsClinical benefitAnti-PD-1 therapyImmune checkpoint inhibitor therapyMRNA expressionQuantitative immunofluorescenceDiagnostic testsCheckpoint inhibitor therapyReal-time quantitative reverse transcription polymerase chain reactionMetastatic melanoma patientsQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionYale Pathology archivesParaffin-embedded tissue sectionsAdjuvant settingICI therapyOS associationInhibitor therapyBaseline variablesMetastatic melanomaPredictive biomarkersPolymerase chain reactionFactors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. DOI: 10.1200/jco.2019.37.15_suppl.540.Peer-Reviewed Original ResearchRisk of BCSMBreast cancer-specific mortalityHR- breast cancerBreast cancerAdjusted riskCumulative riskAnnual event rateCancer-specific mortalityHormone receptor statusBreast cancer deathsEnd Results registryBetter adjuvant therapyKaplan-Meier analysisLong-term riskLate deathsAdjuvant therapyLate relapseReceptor statusHR statusPrimary cancerCox regressionBaseline variablesBlack raceCancer deathClinical trialsFeasibility and effects of galantamine on cognition in humans with cannabis use disorder
Sugarman DE, De Aquino JP, Poling J, Sofuoglu M. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry And Behavior 2019, 181: 86-92. PMID: 31082417, PMCID: PMC6545124, DOI: 10.1016/j.pbb.2019.05.004.Peer-Reviewed Original ResearchConceptsCannabis use disorderEffects of galantamineMeasures of attentionSelf-report measuresAdministration of galantamineOutpatient treatment periodPlacebo-controlled trialParallel-group trialTime pointsAcute cannabis intoxicationSignificant adverse effectsLong-term useSignificant main effectResponse inhibitionCognitive effectsCognitive performanceCognitive outcomesBaseline variablesCognitive AssessmentCognitive deficitsCannabis withdrawalTreatment periodProcognitive effectsGalantamine administrationBaseline sessions
2018
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, Wolk R, Valdez H, Rottinghaus S, Tallman A, Gupta P. Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. Clinical Pharmacology In Drug Development 2018, 7: 587-596. PMID: 29856518, DOI: 10.1002/cpdd.471.Peer-Reviewed Original ResearchConceptsSeparate phase 1 studySevere chronic plaque psoriasisOral Janus kinase inhibitorPharmacokinetics of tofacitinibChronic plaque psoriasisApparent oral clearancePhase 1 studyVd/FCL/FJanus kinase inhibitorFull covariate modelZero-order absorptionOne-compartment modelBaseline PASITofacitinib pharmacokineticsPlaque psoriasisRenal impairmentAdult patientsOral clearancePatient factorsBaseline variablesPharmacokinetic characteristicsBody weightApparent volumeInterindividual variability
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply